Integer Holdings Corporation — Q3 2023 Form 10-Q Summary
Business context and reporting period
Integer Holdings is a medical device outsource manufacturer serving cardiac rhythm management, neuromodulation, cardiovascular, orthopedics, advanced surgical and portable medical markets. It also develops batteries for niche energy, military and environmental applications. The company reports Medical and Non-Medical segments.
The filing covers the 91-day third quarter and 272-day nine-month period ended September 29, 2023, compared with September 30, 2022.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Sales | $404.7 million | $342.7 million | $1,183.5 million | $1,003.7 million |
| Gross profit | $105.6 million | $86.7 million | $308.0 million | $261.1 million |
| Gross margin | 26.1% | 25.3% | 26.0% | 26.0% |
| Operating income | $48.1 million | $29.3 million | $123.8 million | $84.5 million |
| Operating margin | 11.9% | 8.5% | 10.5% | 8.4% |
| Net income | $27.3 million | $16.1 million | $64.3 million | $48.3 million |
| Diluted EPS | $0.81 | $0.48 | $1.91 | $1.45 |
- Medical sales were $395.9 million in Q3, up 19.6%, led by Cardio & Vascular sales growth of 22.9% and Cardiac Rhythm Management & Neuromodulation growth of 21.9%. Non-Medical sales declined 25.3% in Q3.
- Nine-month sales increased 17.9%, while net income increased 33.2%. Management attributed the improvement primarily to strong Medical demand, new product ramps, emerging customers with PMA products, supply-chain improvements, volume leverage and operating efficiencies.
- Cash provided by operating activities was $124.6 million for the first nine months, compared with $64.8 million in the prior-year period. Accounts receivable factoring contributed approximately $30 million to operating cash flow.
- Capital expenditures were $82.9 million, compared with $43.1 million in the prior-year period. Cash and cash equivalents ended at $32.1 million, compared with $24.3 million at December 31, 2022.
- Working capital was $406.2 million and the current ratio was 3.00 at September 29, 2023.
- Debt, net of discounts and issuance costs, was $941.4 million. Debt consisted primarily of $81.2 million drawn on the revolving facility, a $375.0 million Term Loan A and $500.0 million principal amount of 2028 convertible notes.
- The company had $415.3 million of available revolving-credit capacity after outstanding borrowings and letters of credit. The company reported compliance with its debt covenants, including approximately 2.7:1 total net leverage and 7.7:1 interest coverage.
Material changes versus the prior comparable period
- Q3 operating income increased 64.3%, and operating margin expanded 340 basis points to 11.9%. Nine-month operating income increased 46.6%, with margin expanding 210 basis points to 10.5%.
- Q3 gross margin improved 80 basis points due to higher volume leverage and supply-chain efficiency. Nine-month gross margin was unchanged at 26.0%.
- Operating expenses were essentially flat in Q3 despite higher SG&A, because research and development and restructuring costs declined. Nine-month operating expenses increased 4.3%, below the rate of sales growth.
- Interest expense increased 12.1% in Q3 and 66.6% for the first nine months, reflecting higher interest rates, higher average debt and debt-extinguishment costs.
- Restructuring and other charges declined to $0.8 million in Q3 and $3.9 million for the first nine months, compared with $3.1 million and $10.0 million, respectively, in 2022.
- Foreign-currency translation produced an $8.3 million nine-month comprehensive-income reduction, compared with a $61.8 million reduction in the prior-year period.
Guidance, outlook, risks and unusual items
- The filing does not provide a clear quantitative revenue or earnings guidance figure. Management stated that operating cash flow, cash on hand and available revolver capacity are expected to meet working capital, debt service and capital expenditure requirements for the next twelve months.
- In February 2023, Integer issued $500 million of 2.125% convertible notes due 2028. Proceeds were used to repay the Term Loan B, reduce revolver borrowings and fund related costs. Approximately 52% of principal debt was fixed-rate or effectively fixed-rate at quarter-end.
- The company recognized a $3.3 million impairment of a non-marketable equity investment in Q3, contributing to a $3.5 million quarterly loss on equity investments.
- Accounts receivable factoring without recourse totaled $97.4 million during the first nine months; factoring fees were $0.7 million. This accelerated collections but should be considered when assessing underlying operating cash generation.
- On October 1, 2023, after quarter-end, Integer acquired certain InNeuroCo assets for $42 million, subject to working-capital adjustments, with potential contingent consideration of up to $13.5 million and an additional revenue-based payment. The acquisition was funded with revolver borrowings and will be included in the Medical segment.
- Key stated risks include supply-chain disruption, inflation, labor shortages, customer concentration and pricing pressure, reliance on third-party suppliers, manufacturing interruptions, cybersecurity, product quality and regulatory matters, foreign exchange, higher interest rates, substantial indebtedness, covenant compliance and acquisition integration.
- Management reported no material changes to previously disclosed risk factors, no new material legal proceedings, effective disclosure controls and no material changes to internal control over financial reporting.
Most important facts for investors to verify
- Whether Medical-segment growth and new product ramps remain durable, particularly in Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation.
- The sustainability of operating-margin improvement after supply-chain normalization, labor-cost increases and ongoing capacity investments.
- Underlying cash generation excluding the benefit of receivables factoring, and the effect of elevated inventory and contract assets.
- Interest-rate sensitivity of the remaining floating-rate debt and continued compliance with leverage and interest-coverage covenants.
- The financing, purchase-price allocation, contingent consideration and integration performance of the InNeuroCo acquisition.
- Potential dilution or cash obligations associated with the 2028 convertible notes, including the effect of the capped-call transactions.